anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: veterinary science. SUBSTANCE: the present innovation deals with antimicrobial preparations applied for treating acute post partum endometritis in cows and methods for their application. The suggested preparation includes antimicrobial substance as quinosol and, additionally, it contains hydrogen peroxide, carbocholine, distilled water, methyl cellulose and trilon-B at the following ratio of components, g/l solution: quinosol 1.5-2.5, hydrogen peroxide 2.0-3.0, carbocholine 0.5-1.0, methyl cellulose 10- 15, trilon-B 0.5-1.5, distilled water the rest. The method for treating acute post partum endometritis in cows deals with introducing preparation including antimicrobial substance at the dosage of 50-100 ml once daily for 3-5 d. The suggested innovation enables to increase economic efficiency of therapy due to decreased labor expenses, shortened terms of therapy by 1.8-2.0 times and quantity of sterility days by 1.4 times. EFFECT: higher efficiency of therapy. 2 cl
A dittany phenol glycoside D and a preparation method and application thereof relate to a novel compound, a preparation method and application thereof. The invention aims to provide a novel compound dittany phenolic glycoside D, a preparation method and application. Dictamni phenolic glycoside D has a molecular formula of C  22  H  34  O  11  The molecular weight is 474.2101. The preparation method comprises the following steps: 1. pulverizing cortex Dictamni Radicis, and extracting with ethanol; 2. dispersing the ethanol-recovered extract with water, and sequentially extracting with petroleum ether, chloroform and ethyl acetate; 3. separating ethyl acetate extract by silica gel column chromatography, reversed phase silica gel column chromatography, and preparative high performance liquid chromatography. IC of the NO release rate of dictamnin D on LPS-induced inflammatory mouse macrophages (RAW 264.7)  50  Is 12.37 mu M/L, and has better in vitro anti-inflammatory activity; IC for inhibiting lung adenocarcinoma cells (A549) and liver cancer cells (HepG 2)  50  Respectively 14.57 mu M/L and 12.26 mu M/L, and has better in vitro anti-tumor activity. The invention belongs to the field of research on active ingredients of natural medicines.
BACKGROUND: Periodontitis is closely associated with chronic systemic diseases. Healthy lifestyle interventions have health-enhancing effects on chronic systemic disorders and periodontitis, but the extent to which healthy lifestyle combinations are associated with periodontitis is unclear. Therefore, this study aimed to investigate the association between periodontitis and different healthy lifestyle combinations.
METHODS: 5611 participants were included from the National Health and Nutrition Examination Survey (NHANES, 2009-2014). Six healthy lifestyles factors were defined as fulfilling either: non-smoking, moderate drinking, moderate body mass index (BMI), physical activity, healthy sleep and appropriate total energy intake. Then, the adjusted logistic regression models were performed to identify the association between the periodontitis and the scoring system composed of six lifestyles (0-6 scale). Finally, different scenarios were dynamically and randomly combined to identify the optimal and personalized combination mode.
RESULTS: Higher healthy lifestyle scores were significantly associated with lower periodontitis prevalence (p < 0.05). Four lifestyle factors (smoking, drinking, BMI, and sleep) significantly varied between the periodontitis and healthy groups (p < 0.05). Smoking was considered as a strong independent risk factor for periodontitis in both former and current smokers. Results further indicated that the combination of these four lifestyles played the most essential role in determining the magnitude of periodontitis occurrence (odds ratio [OR]: 0.33; 95% confidence interval [CI]: 0.21 to 0.50). In the total population, the majority of three lifestyle combinations outperformed the two combination models, whereas the two-combination of nonsmoking-drinking (OR: 0.39; 95% CI: 0.27 to 0.58) had relatively lower periodontitis prevalence than the three-combination of healthy drinking-BMI-sleep (OR: 0.42; 95% CI: 0.26 to 0.66).
CONCLUSION: This cross-sectional study suggests that smoking, drinking, BMI, and sleep are significantly related with periodontitis and smoking is the principal risk factor related among them. This study provides various customized lifestyle combinations for periodontitis prevention.
Adult and Adolescent Patients Aged 12 Years and Older

The safety of ASMANEX HFA was evaluated in 2 randomized placebo and active-controlled trials of 12 and 26 weeks' duration, conducted as part of a mometasone furoate/formoterol fumarate combination product asthma program, which enrolled 1509 patients with persistent asthma. Patient ages ranged from 12 to 84 years of age, 41% were male and 59% female, 73% were Caucasian and 27% non-Caucasian. Of the total population enrolled in the 2 trials, 432 patients received two inhalations twice daily of either ASMANEX HFA, 100 mcg or 200 mcg/actuation. In the 26-week trial (Trial 1) 192 patients received two inhalations twice daily of ASMANEX HFA 100 mcg/actuation and 196 patients received placebo. In the 12 week trial (Trial 2) 240 patients received two inhalations twice daily of ASMANEX HFA 200 mcg/actuation and 233 and 255 patients received mometasone furoate and formoterol fumarate 100 mcg/5 mcg and 200 mcg/5 mcg/actuation combination products, respectively, as comparators. 

In these trials, the proportion of patients who discontinued study treatment early due to adverse reactions was 3% and 2% for ASMANEX HFA 100 and 200 mcg treated patients, respectively, and 4% for placebo-treated patients. Serious adverse reactions, whether considered drug-related or not by the investigators, which occurred more frequently in ASMANEX HFA-treated patients included colitis ulcerative, colonic polyp, chest pain, gastroenteritis, endometriosis, asthma, and hemoptysis; all events occurred at rates less than 1%.

The incidence of treatment emergent adverse events associated with ASMANEX HFA are shown in Tables 1 and 2. These are based upon data from each of the 2 clinical trials of 12 or 26 weeks in duration in patients 12 years and older treated with two inhalations twice daily of ASMANEX HFA (100 mcg or 200 mcg), mometasone furoate/formoterol fumarate (100 mcg/5 mcg or 200 mcg/5 mcg), or placebo.

Oral candidiasis has been reported in clinical trials at an incidence of 0.5% in patients using ASMANEX HFA 100 mcg, 0.8% in patients using ASMANEX HFA 200 mcg and 0.5% in the placebo group.

Pediatric Patients Aged 5 to Less Than 12 Years

The safety profile for ASMANEX HFA 50 mcg, 2 inhalations twice daily, is based on two clinical trials consisting of a total of 759 patients aged 5 to less than 12 years with persistent asthma. The first trial was a placebo-controlled trial comparing ASMANEX HFA 50 mcg (administered as 2 inhalations, twice daily) to 2 other dosage strengths of mometasone furoate MDI (25 mcg or 100 mcg, each administered as two inhalations, twice daily) as well as mometasone furoate DPI 100 mcg, administered as one evening inhalation. The second trial compared ASMANEX HFA 50 mcg to the combination of mometasone furoate and formoterol fumarate 50 mcg/5 mcg, each administered by MDI as two inhalations, twice daily. 

Overall, the safety profile for pediatric patients is similar to that observed in patients aged 12 years and older.
Patients who are planned to have an erector spina block will be advanced to the interfacial area under the erector spinae muscle by ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.
PROBLEM TO BE SOLVED: To obtain a hair treating agent composition capable of increasing both a permeation rate and amount to hair, having no sensitizing potential, at a low production cost. SOLUTION: This hair treating agent composition contains 0.1-15wt.%, preferably 1-5wt.% of a compound of the formula CH3 C6 H4 OCH2 CH2 OH as a permeation promoter. Since the compound of the formula has the same permeation promoting effect as that of benzyl alcohol as a conventional permeation promoter, and is extremely weak in aroma or substantially odorless, it can impart aimed aroma to a hair treating agent. The hair treating agent composition can be mixed with a dye (e.g. black 401), a keratin reducing agent (e.g. thioglycolic acid), etc., and can be prepared into a cream, emulsion, gel, mousse or a foamy state. The compound of the formula is obtained by adding 1mol ethylene oxide to the phenolic hydroxyl group of cresol.
Background and Objectives: The safe zone in total hip replacement was introduced many years ago. Its aim was to provide guidelines for orthopedic surgeons in order to avoid complications such as instability. With the growing interest in spinopelvic alignment, some new insights suggest that the safe zone is an obsolete concept. This study aims to show that, even outside the safe zone, the effect of total hip replacement can be satisfactory. This could be used as preliminary study for an analysis of a larger group. Materials and Methods: Fifty-nine consecutive patients with end-stage osteoarthritis treated by total hip replacement were enrolled into the study and divided into two groups: inside the safe zone and outside the safe zone. A physical examination during postoperative visits was performed; the range of movement was measured using a goniometer; and the HHS and VAS were taken to measure functional outcomes and pain, respectively. An analysis of the radiological outcomes was performed. Results: There was no significant difference in regard to changes in total offset, pain, HHS and other complications. There were no signs of instability among patients during the follow-up. Conclusions: The results of this study show that the "safe zone" is a more complicated term that was previously thought. A proper soft tissue balance and spinopelvic alignment could be factors that change the "safe zone" for each patient and make it more individual.
GRANIX may be administered by either a healthcare professional, a patient or caregiver. Before a decision is made to allow GRANIX to be administered by a patient or caregiver, ensure that the patient is an appropriate candidate for self-administration or administration by a caregiver. Proper training on storage, preparation, and administration technique should be provided. If a patient or caregiver is not an appropriate candidate for any reason, then in such patients, GRANIX should be administered by a healthcare professional.

Dispense only the prefilled syringe without a safety needle guard device to patient or caregiver. Instruct patients and caregivers to follow the Instructions for Use provided with the GRANIX prefilled syringe to properly administer an injection after training by a healthcare professional.  


Visually inspect parenteral drug products for particulate matter and discoloration prior to administration. Do not administer GRANIX if discoloration or particulates are observed.  


The prefilled syringe and vial are for single-dose only. Discard unused portions. GRANIX and all its components are not made with natural rubber latex.  


Recommended sites for subcutaneous GRANIX injections include the abdomen (except for the two-inch area around the navel), the front of the middle thighs, the upper outer areas of the buttocks, or the upper back portion of the upper arms. The injection site should be varied daily. GRANIX should not be injected into an area that is tender, red, bruised, or hard, or that has scars or stretch marks.
A traditional Chinese medicine new-technology formula. The traditional Chinese medicine new formula, which is a personal intellectual property invention, in the invention belongs to nation, to the nationality and also to the world. The traditional Chinese medicine new formula is researched through human explore genetic resource function and is the first research result in our country. According to a non-official intellectual activity rule and a non-official intellectual activity method, a first-generation traditional Chinese medicine new-technology formula, a second traditional Chinese medicine new-technology formula and a third traditional Chinese medicine new-technology formula are invented. On the basis of the 26th article  in "patent law of the people's republic of China", this non-official invention provides the first relative result which is incredible and proves that the gold will shine everywhere. In the first generation, American ginseng is combined with cordyceps sinensis to achieve public health caring; in the second generation, the American ginseng is combined with cordyceps militaris (Northern cordyceps sinensis); in the third generation, the American ginseng is combined with the cordyceps militaris (cordyceps cicadae) cordyceps sinensis, wherein the three generations all have the function of genetic resources, so that cardiocerebral vascular system diseases and blood vessel obstruction can be eliminated and discharged directly. The traditional Chinese medicine new-technology formula is a beginning of world-best innovation for human public health.
There is no consensus on the optimal treatment of de novo donor specific antibody-mediated rejection. Optimizing baseline immunosuppression (calcineurin inhibitor (CNI), anti-proliferative agent, and anti-inflammatory) is considered foundational but is insufficient. Pulse steroids are routinely used. A number of immunosuppressive approaches have been tried in uncontrolled trials. The strongest evidence, at least for early antibody-mediated rejection (\< 6 months from transplant), exists for plasmapheresis, with or without low dose IVIg, or high dose IVIg alone. However, as noted in a recent FDA workshop, "while the literature suggests that \[these agents\] have evidence of efficacy for the management of acute antibody-mediated rejection, and could be considered as standard of care, treatment regimes have not been standardized or optimized." Moreover the evidence supporting efficacy of this approach in late, as opposed to early antibody-mediated rejection is distinctly lacking.
This is an open-label, single arm, pilot study in patients with severe, poorly-controlled eosinophilic asthma to quantify hyperpolarized 129-Xenon MRI ventilation defect percent (VDP) before and after benralizumab therapy administered every 4 weeks for the first three injections (subcutaneous injection). Male and female patients between 18 and 70 years of age will be screened (Enrolment, Visit 1) and those that satisfy all inclusion and exclusion criteria will undergo five additional two-hour study visits (Visit 2=Day 0/baseline, Visit 3=Day 14±2 days and Visit 4=Day 28±2 days, Visit 5=Day 56±2 days, Visit 6=112±2 days) which will involve spirometry, plethysmography for airways resistance (Raw) and lung volumes, forced oscillation technique (FOT), multiple breath nitrogen washout (MBNW) for the lung clearance index (LCI) and 129-Xenon MRI pre- and post-bronchodilator, with the exception of Visit 5, which will not include MRIs. At all visits fractional exhaled nitric oxide (FeNO) will be measured pre-bronchodilator. The Asthma Control Questionnaire (ACQ-6), the Asthma Quality of Life Questionnaire (AQLQ) and the St. George's Respiratory Questionnaire (SQRQ) will be completed at all visits except Visit 3. Sputum induction will be performed on Visits 2 and 4 to measure sputum eosinophils, and blood samples will be performed on Visits 1 and 4 to measure blood eosinophils. Participants that satisfy all inclusion and exclusion criteria will complete a total of six study visits. Upon study enrolment, all participants will be allocated to a benralizumab treatment arm (30 mg injection after completion of study assessments on Visit 2/Day 0, Visit 4/Day 28 and Visit 5/Day 56). After Visit 6/Day 112, all participants will be offered participation in the AstraZeneca Patient Support Program to receive benralizumab therapy on Day 112 and every 8 weeks thereafter.
<P>PROBLEM TO BE SOLVED: To provide a specimen test device reducing a risk of accidentally outputting personal information to outsiders by a technician and enabling a user to output analysis results including required personal information, and also to provide a test information management device.  <P>SOLUTION: An information processing unit 5 is equipped with: a CPU 51a; and a hard disk 51d including a user authentication table TB1, a patient attribute information table TB2 and a test result table TB3. When a user logs in to a specimen test device, the information processing unit 5 accepts input of a user ID and password to perform user authentication. The user who has logged in is a general user, patient attribute information including a patient ID, the patient's name, a doctor in charge, a hospital ward, comments of the patient and the like is output with test results. When the user who has logged in is a technician, the test results are outputted without outputting the patient attribute information.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Survival and neurological recovery after out-of-hospital cardiac arrest are highly variable, driven in part by inconsistent hospital care following successful resuscitation. International guidelines for post-cardiac arrest care recommend delaying neurologic prognostication until 72-hours after resuscitation because early prognostication is imprecise and may precipitate inappropriate withdrawal of life sustaining therapy (WLST). Early WLST has been observed in-post cardiac arrest care. In order to encourage better guideline concordant care, the study proposes the implementation of an educational tool to support and inform surrogate decision makers in post-cardiac arrest care and neuro-prognostication. This pilot study will test the feasibility of implementing an educational tool for surrogate decision makers, the acceptability of such an intervention and early measures of knowledge translation. This study will inform the creation of a randomized controlled trial to test the ability of the tool to encourage guideline concordant timing of post-cardiac arrest neuro-prognostication.
A comprehensive evaluation of cardiovascular (CV) risk with varenicline suggests that patients with underlying CV disease may be at increased risk; however, these concerns must be balanced with the health benefits of smoking cessation. CV risk has been assessed for varenicline in randomized controlled trials (RCT) and meta-analyses of RCTs. In a smoking cessation trial in patients with stable CV disease, CV events were infrequent overall; however, nonfatal myocardial infarction (MI) and nonfatal stroke occurred more frequently in patients treated with varenicline compared to placebo. All-cause and CV mortality was lower in patients treated with varenicline [see Clinical Studies (14.8)]. This study was included in a meta-analysis of 15 varenicline efficacy trials in various clinical populations that showed an increased hazard ratio for Major Adverse Cardiovascular Events (MACE) of 1.95; however, the finding was not statistically significant (95% CI: 0.79, 4.82). In the large postmarketing neuropsychiatric safety outcome trial, an analysis of adjudicated MACE events was conducted for patients while in the trial and during a 28 week non-treatment extension period. Few MACE events occurred during the trial; therefore, the findings did not contribute substantively to the understanding of CV risk with varenicline. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of MI or stroke [see Clinical Studies (14.10)].
FIELD: medical engineering. SUBSTANCE: material has porous permeable titanium nickelide crumbs with particle size of 0.1-1.0 mm. When using the material, bone defect is filled with titanium nickelide crumbs and covers with surrounding tissues. High strength composite of titanium nickelide-bone is built due to osteogenesis developing with time to reliably substitute the lost bone volume. EFFECT: simplified material preparation and surgical treatment method. 2 dwg
The invention belongs to the technical fields of medicine and food, and in particular provides a compound for preventing and treating gastric mucosal damage. The compound provided by the invention is prepared by mainly mixing grape seed, panax notoginseng and hericium erinaceus in any percentages by weight. Preferably, the weight ratio of the grape seed to the panax notoginseng to the hericium erinaceus is 1 to 1 to 1. Meanwhile, the invention also provides a preparation method and application of the compound. The compound provided by the invention has the beneficial effects that the compound has a significant curative effect on the aspects of preventing and treating the gastric mucosal damage, and moreover the compound, which is completely prepared from natural plants, is low in side effects and is especially suitable for preventing and treating repetitive gastric mucosal damage caused by long-term medicine taking and alcohol drinking. Meanwhile, according to the preparation method provided by the invention, active ingredients in the various raw materials has high extraction rate and high content, so that the curative effect of the prepared compound is further improved finally.
This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; pulmonary group are those who have reported any pulmonary diseases and they will be included in this study as pulmonary group.
Progressive relaxation exercises will be explained and taught to the puerperant after cesarean section. Experimental Group (in the group where progressive relaxation exercises were applied); The first application will be made at the 8th postoperative hour. Before the application, the Puerperal Identification Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled out. Starting from the 8th post-op hour, the first, second and third applications will be made eight hours apart within a 48-hour period. On the second day, progressive relaxation exercises will be performed once, twice and three times at eight-hour intervals. At the end of the second day, the Postpartum Definition Form, Beck Anxiety Scale, Visual Analogue Scale (VAS) and Physiological Parameters forms will be filled in again.
PURPOSE:To composition to abstain from smoking that contains a powder or foils of metallic silver or a noble metal alloy thereof, thus making the smoking taste hateful selectively to reduce smoking desire without any adverse effect on bodies. CONSTITUTION:The objective composition contains powder, foils, strips or pieces of metallic silver and an alloy thereof with noble metal. The content of the metallic silver or its alloy is preferably 0.05-50mg each application. The alloy of metallic silver is preferably more than 20wt% silver content. Metallic silver or its alloy is made into a powder or foil and combined with an appropriate base such as candy or chewing gum. When the product is chewed in the mouth, the silver molecules act on the gustatory nerves to give a sense detesting tobacco smoke selectively.
PURPOSE: A composition and a functional food containing Galla Rhois ethanol extract are provided to suppress kidney cancer cell growth and to induce kidney cancer cell apoptosis. CONSTITUTION: A composition for preventingn and treating kidney cancer contains Galla Rhois ethanol extract as an active ingredient, prepared using 95% ethanol at 50 Deg. C. for 24 hours. The composition also contains pharmaceutically acceptable carriers or diluents. A functional food for preventing kidney cancer contains the Galla Rhois ethanol extract as an active ingredient, and sitologially acceptable food additives. [Reference numerals] (AA) Relative cell survival rate